Stay updated on HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Sign up to get notified when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.

Latest updates to the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record, with the 403 header and a site footer visible, indicating the trial details are inaccessible at this time.SummaryDifference19%

- Check36 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6. This reflects a version bump for the page rather than a substantive change to study details.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, representing a small backend/content management update.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page’s revision metadata updated from v3.6.3 to v3.6.4, indicating a new version of the page.SummaryDifference0.1%

- Check93 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, reflecting a minor update to the study record documentation.SummaryDifference0.1%

- Check100 days agoChange DetectedThe revision tag in the page footer was updated from v3.6.0 to v3.6.2, indicating a newer platform release.SummaryDifference0.1%

Stay in the know with updates to HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.